CN Patent

CN112574196A — 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成

Assigned to Daiichi Sankyo Co Ltd · Expires 2021-03-30 · 5y expired

What this patent protects

一种调节激酶的1H‑吡咯并[2,3‑b]吡啶衍生物的合成。本公开提供用于制备式(I)化合物：或其盐的方法，所述式(I)化合物或其盐作用于受体蛋白激酶c‑Kit和/或c‑Fms和/或Flt3。本公开还提供所述式(I)化合物的合成中间产物的化合物和用于制备所述化合物的方法。

USPTO Abstract

一种调节激酶的1H‑吡咯并[2,3‑b]吡啶衍生物的合成。本公开提供用于制备式(I)化合物：或其盐的方法，所述式(I)化合物或其盐作用于受体蛋白激酶c‑Kit和/或c‑Fms和/或Flt3。本公开还提供所述式(I)化合物的合成中间产物的化合物和用于制备所述化合物的方法。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN112574196A
Jurisdiction: CN
Classification: —
Expires: 2021-03-30
Drug substance claim: No
Drug product claim: No
Assignee: Daiichi Sankyo Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.